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Summary 
 
Non-invasive, real time optical imaging methods are particularly well suited for the in vivo 
follow up of the distribution of nucleic acids nanocarriers, their dissociation and finally the 
resulting gene expression or inhibition. Indeed, most small animal imaging devices are 
performing bioluminescence and fluorescence measurements without moving the animal, 
allowing a simple, rapid and cost effective method of investigation of several parameters at a 
time, in longitudinal experiments that can last for days or weeks. 
Here we propose to help the reader choosing adapted near-infrared (NIR) fluorophores or 
pairs of fluorophores for FRET assays, reporter genes as well as nanocarriers for in vivo gene 
and siRNA delivery. In addition, we present the labeling methods of these macromolecules, 
and of their payload and the protocols to detect them using bioluminescence and NIR 
fluorescence imaging in mice. 
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 1. INTRODUCTION 
 
Optical imaging based on 2D Fluorescence reflectance (FRI), is a non-invasive method, that 
allows to follow molecules injected into a mouse in real time, at a good spatial (nm to mm 
range) and temporal resolution (µ to msec), a high sensibility (femto- to pico-molar range) 
and from whole-body down to the subcellular scale. However, the information that can be 
obtained through absorbing biological tissues is strongly depth-weighted and depends on the 
thickness and optical properties of the tissues to be imaged. This method is thus only semi-
quantitative. The tissues are less absorbing in a near-infrared (NIR) spectral window ranging 
from 650 nm to 900 nm and it is thus important to use adapted fluorophores whenever 
possible.  
The recent description of increasing amounts of organic or in-organic NIR fluorochromes 
contributed to the development of optical imaging methods for the investigation of deep 
tissues (1, 2). These fluorophores, or combination of them can be used for labeling molecules 
of interest and will accelerate significantly the preclinical studies. By separately labeling the 
vector and the nucleic acid using an adapted pair of fluorophores, we can provide direct 
information on the distribution of the intact particle, its capacity to release the nucleic acid, 
the subcellular distribution of each component, and finally a direct measure of the reporter 
gene expression. 
Several reporter genes of the luciferase family are adapted to bioluminescence imaging in vivo 
(BLI), while the very commonly used fluorescent proteins like Green Fluorescent proteins 
(GFP), RedFP, etc…can be used in FRI but are more adapted for in vitro applications because 
they emit in the visible spectrum. ß-galactosidase, an enzyme encoded by the lacZ gene of 
Escherichia coli can also be followed in vivo using NIR substrates like DDAOG (3). 
Thus by combining FRI and BLI, we can obtain multiple information especially well suited 
for the evaluation of the biodistribution of lipid nanocapsules(LNC) or polyethilenimine (PEI) 
polyplexes, or cell penetrating peptides (CPPs), three non-viral systems well suited for the 
delivery of DNA and siRNA in mice (4-6). 
 
  
 2. MATERIALS 
 
2.1. Fluorophores 
Commercially available fluorophores are declined in a wide variety of wavelength, 
hydrophilicity and reactive moieties. Since the choice of absorption and emission wavelength 
mainly depends on the available apparatus, we will here focus on selection criteria for 
hydrophobicity/hydrophilicity and chemical reactivity (Table 1). 
 
2.2  FRET, dark dye quenching, and wavelength selection 
Even with the right fluorophore, fluorescence imaging will only reveal the molecule location 
independently of the nanoparticle. Förster resonance energy transfer (FRET) occurs between a 
donor and a receptor dye within the range of the Förster radius, typically ranging from 5 to  
10 nm depending on the pair considered. This property makes it a useful phenomenon to 
gather information in the nanometric range through spectroscopic methods. When donor and 
acceptor dyes are in close vicinity, excitation of the former can be passed to the latter via non-
radiative pathways. Macroscopically, FRET is attested by a decrease of the donor 
fluorescence and an increase of the acceptor emission upon irradiation of the donor. It is 
therefore possible to know whether or not dyes are still encapsulated within a nanoparticle by 
studying its emission spectrum: upon excitation of the donor, free dyes will display normal 
donor fluorescence while nanoparticles will display strong acceptor emission. 
Dark dye quenching is also based on FRET, except that the acceptor dye is non-fluorescent. In 
this case, the energy transfer result in a decrease of the donor emission while the acceptor 
remains non-fluorescent. This results in a simple on/off switch in fluorescence, where 
emission is recovered when the dyes are released from the nanoparticle. Though this method 
provide a more straightforward mean to track where and when the dyes escapes from the 
nanoparticle, it also means that (contrary to classical FRET method) circulating nanoparticles 
are non-fluorescent and can not be tracked through spectroscopic method unless a third dye is 
introduced. 
To occur, FRET requires that spectral absorption of the acceptor overlaps sufficiently with the 
donor emission. Though precise calculations are required, this generally means that 
absorption peaks of the donor and acceptor should be spaced by approximately 50 to 100 nm. 
On the one hand, with less than 50 nm, spectral overlap between donor and acceptor 
emissions might hinder FRET measurements. On the other hand, spectral differences of more 
than 100 nm will often result in low a spectral overlap, therefore very short Förster radii. The 
following table provides a few examples of near-infrared dyes (fluorescent or dark dyes) 
along with possible FRET pairing (Table 2 and 3). 
 
2.3 Nucleic acids 
Two types of nucleic acids will be presented: DNA or/and siRNA. In each case, high-quality 
plasmids or small interfering RNA (siRNA) preparations should be used. 
Plasmid reporter genes 
To visualize the efficiency and biodistribution of in vivo gene delivery, different reporter 
genes can be used. For in vivo bioluminescence, plasmids encoding for firefly luciferase are 
very commonly used (pgWIZ-luciferase (GENLANTIS, San Diego, USA) by example). The 
bacterial ß-galactosidase gene expression can be detected in vivo using near infrared 
fluorescent imaging (NIR). For plasmid DNA, OD260/280 ratio should be greater than 1.8. It is 
best to use DNA prepared in water, free of salt, RNAs, proteins or endotoxins.  
Tracking of small interfering RNA (siRNA) 
Concerning siRNA (21–23 nucleotides duplex RNA with symmetric 2 nucleotides 3’ 
overhangs), we use high-quality desalted siRNA (PAGE or HPLC purified). As for 
primer/probe design, a G/C content around 50% is usually selected and oligonucleotides with 
three or more of any purinenucleotide in a row are avoided. Prediction algorithms provide 
some guidance for siRNA sequence selection (Note 1). 
 
2.4  DiD-DNA-lipid nanocapsules (LNC) compounds 
Lipoplexes compounds 
Cationic lipids used are DOTAP (1,2-DiOleoyl-3-TrimethylAmmonium-Propane) and DOPE 
(1,2-DiOleylsn-glycero-3-PhosphoEthanolamine) (Avanti Polar Lipids, Inc, Alabaster, USA). 
Plasmid DNA (pDNA) is a pgWIZ-luciferase (GENLANTIS, San Diego, USA) amplified and 
research grade purified by GENEART (Regensburg, Germany).   
LNC components 
DNA LNCs are composed of an oily core of Labrafac® WL 1349 (caprylic-capric acid 
triglycerides, European Pharmacopeia, IVth, 2002) and oleic Plurol® (Polyglyceryl-6 
dioleate) which were kindly provided by Gatefosse S.A. (Saint-Priest, France) and a corona of 
tension active Solutol® HS-15 (30% of free polyethylene glycol 660 and 70% of polyethylene 
glycol 660 hydroxystearate (HS-PEG) European Pharmacopeia, IVth, 2002) which was a gift 
from BASF (Ludwigshafen, Germany) (7). 
DiD fluorochrome (1,10-dioctadecyl-3,3,30,30-tetramethylindodicarbocyanine perchlorate 
(DiD, em. = 644 nm; exc. = 665 nm) was provided by Invitrogen (Carlsbad, CA, USA). 
DiD labeled DNA LNCs are purified thanks to PD10 Sephadex columns (Amersham 
Biosciences Europe, Orsay, France) containing Sephadex™ G-25. A second purification and 
a concentration step are then performed by ultrafiltration thanks to Millipore Amicon® Ultra-
15 centrifugal filter devices (Millipore, St Quentin-Yvelines, France). 
Post inserted polymer  
1,2-DiStearoyl-sn-glycero-3-PhosphoEthanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(DSPE-mPEG2000) (Mean Molecular Weight (MMW) = 2805 g/mol) was provided from 
Avanti Polar Lipids (Inc, Alabaster, USA) 
Special equipment  
Size, polydispersity index, or surface charge (zeta potential) of DiD labeled DNA LNCs, post 
inserted or not, can be measured using a Malvern Zetasizer® (Nano Series DTS 1060, 
Malvern Instruments S.A., Worcestershire, UK). 
 
2.5 Fluorescent labeling of peptide  
For purification of CADY by semi-preparative reverse-phase high performance liquid 
chromatography (RP-HPLC), we use C18 column Interchrom UP5 WOD/25M Uptisphere 
300 5 ODB, 250 mm x 21.2 mm. For labeling, we use maleimide dyes (maleimide-FITC or 
Maleimide-Alexa) from Molecular Probes. Inc (Invitrogen, Carlsbad, CA, USA). 
 
2.6 PEI DNA complex 
Polyethylenimine (PEI) is a linear cationic polymer widely used in vivo for delivery of many 
nucleic acid including plasmid DNA, oligonucleotides and siRNA without triggering an 
immune response. PEI is widely used in animal models and also in the clinic. For in vivo 
transfection, we use “in vivo-jetPEI™” (Polyplus-transfection, Ilkirch, France). “In vivo-
jetPEI™” mediates efficient nucleic acid delivery in a wide range of tissues, using various 
delivery routes: intravenous (IV), intraperitoneal (IP), intratumoral, intracardiac, sub-
cutaneous, topical, intrathecal, intra-cerebral, etc. Upon IV administration, high levels of 
nucleic acid delivery are achieved in the lung. Other organs such as heart, spleen, pancreas 
and liver are also transfected following IV injection. In addition “in vivo-jetPEI™” is an 
effective carrier for local gene delivery such as intratumoral or topical application on the skin. 
More recently “in vivo-jetPEI™” has become a powerful tool for in vivo RNA interference 
experiments. 
 
2.7 Animals 
All animal experiments are conducted in agreement with the “Principles of laboratory animal 
care” (NIH publication No. 86-23, revised 1985) and approved by the local ethical 
Committee. Optical imaging experiments are conducted on female 6-8 weeks old nude mice. 
 
2.8 D-Luciferin 
Powder (Promega, Charbonnières, France) is dissolved in DPBS without CaCl2 and MgCl2at 
100 mg/mL.The solution is sterilized by filtrationacross a 0.2 µm membrane and stored at -
80°Csheltered from light. 
 
2.9 DDAOG 
9H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-yl) ß-D-galactopyranoside (Molecular Probes, 
Invitrogen, Carlsbad, CA, USA) is dissolved in DMSO/PBS v/v to get 5 mg/mL. 
 
2.10 Fluorescence imaging set-up 
Illumination is made by 633 or 660 nm Light Emitting Diodes (LEDs) equipped with 
interference filters. Fluorescence images are acquired with a back-thinned CCD cooled  
(-70°C) Camera (ORCAII-BT-512G, Hamamatsu Photonics, Massy, France) filtered either by 
a colored glass long pass filter RG 665plus a band pass filter 680 (MellesGriot, Voisins le 
Bretonneux, France)when illuminating at 633 nm or a high pass filter RG 9 (Schott, Clichy, 
France) when illuminating at 660 nm. 
 2.11 Common Reagents  
PBS pH 7.4 (Gibco, Invitrogen, Carlsbad, CA, USA), Ultra-Pure DNAse–RNAse-free Sterile 
Water (GIBCO; Invitrogen, Carlsbad, CA, USA), dimethyl sulfoxide (DMSO) (Sigma; Saint-
Quentin Fallavier, France), chloroform (Sigma, Saint-Quentin Fallavier, France)  
 
 
  
 3. METHODS 
 
3.1 Nanocarriers labeling and Nucleic acids and 
nanocarrierscomplexation 
3.1.1 DiD labelled DNA LNC formulation 
Lipid nanocapsules (LNCs) were developed according to a solvent-free process based on an 
emulsion phase inversion. DNA complexed with cationic lipids i.e. DOTAP/DOPE, was 
encapsulated into LNCs leading to the formation of stable nanocarriers (DNA LNCs) with a 
size inferior to 130nm. Amphiphilic and flexible poly (ethylene glycol) (PEG) polymer 
coating [PEG lipid derivative (DSPE-mPEG2000)] at different concentrations was selected to 
make DNA LNCs stealthy.. 
a) Preparation of the aqueous phase (containing DNA and cationic liposome complexes) 
1. Dissolve DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) and DOPE (1,2-
dioleyl-sn-glycero-3-phosphoethanolamine) in chloroform at a concentration of 20 
mg/ml. To obtain a final concentration in positive charge of 25mM [+] in 3ml, mix 
DOTAP/DOPE at a molar ration of (1:1), i.e add 2.617 ml of DOTAP solution  
(20 mg/ml) to 2.790 ml of DOPE (20 mg/ml) in a 25 ml balloon and assure a 
homogeneous mixture of lipids (Note 2). 
2. Once the lipids are thoroughly mixed in the organic solvent, remove the organic 
solvent by rotary evaporation at room temperature, under vacuum to yield a thin lipid 
film without solvent residues.  
3. Hydrate the dry lipid film by adding 3ml of purifying deionized water (18 MΩ.cm, 
MilliQ), and incubate over night at 4°C. 
4. After this incubation step, vigorously mix the lipid suspension by vortexing. The thus-
formed multilamellar vesicles are sonicated 20 min in a bath sonicator to allow the 
formation of small unilamellar vesicles. 
5. To form lipoplexes, mix DNA and cationic liposomes at a charge ratio (±) of 5 in  
150 mM NaCl. Briefly, add 660 µg of pDNA in a solution containing 300 mM NaCl 
to obtain a final concentration of 660 µg of pDNA in 400µl NaCl. Then add the same 
volume of previously synthesized cationic liposomes (400 µl). Mix thoroughly with a 
pipette, and let incubate 30 min before use. 
b) Preparation of the lipid phase (containing DiD stained Labrafac®) 
1. Dissolve 5 mg of DiD in 1 ml of Acetone, to obtain a final solution at 5 mg/ml in a 
scintillation bottle. Gently mix 2h.  
2. Mix 100 mg of 5 mg/ml DiD solution with 900 mg of Labrafac®. Mix 15 min, and let 
the bottle open under a cell culture hood during 2-3 hours to allow the acetone 
evaporation. Control the whole acetone evaporation by weighting before and after 
evaporation. 
c) Preparation of DiD labeled DNA LNCs 
1. Weigh all the LNC components in a scintillation bottle. First weigh 58 mg of Solutol 
HS-15
®
(Note 3), then add 38.7 mg of oleic Plurol®, 96.16 mg of DiD stained 
lipophilic Labrafac® (cf.2.b)), 14.1 mg of NaCl and 800 µl of aqueous solution 
containing lipoplexes (cf. 2.a)) 
2. Mix all the components together under magnetic stirring and heat to 60°C thanks to a 
hot plate stirrer. 
3. Six temperature heat-cooling cycles were applied between 20 and 60°C, still under 
magnetic stirring, to obtain a phase inversion from an oil-in-water to a water-in-oil 
emulsion. Change in color can be observed in a zone between these two emulsions. In 
this region, the system appeared translucent with blue glints, which is representative of 
microemulsions, this zone was called the phase inversion area (7). After these 
temperature cycles, in the phase inversion zone, the mixture underwent a fast cooling-
dilution process with 500µl of cold water (4°C), leading to the formation of DiD 
labeled DNA LNCs in water (Note 5). 
4. Control the size, polydispersity and surface charge (zeta potential) of DiD labeled 
DNA LNCs thanks to dynamic light scattering (DLS, size) and electrophoretic 
mobility (zeta potential) (ex. Malvern Zetasizer®, Nano Series DTS 1060, Malvern 
Instruments S.A., Worcestershire, UK). 
5. Control the encapsulation properties of DiD labeled DNA LNCs thanks to 
electrophoresis migration of broken (Triton X100) or intact DNA LNCs in an agarose 
gel (1%) containing ethidium bromide (method developed in (5, 8, 9)). 
d) Purification of DiD labeled DNA LNCs 
1. Equilibrate a PD10 Sephadex® column with approximately 25 ml elution buffer.  
2. Add DiD labeled DNA LNC suspension of a total volume of 2.5 ml per column. If the 
volume is less than 2.5 ml, then add buffer until the total volume of 2.5 ml is achieved. 
3. Elute with buffer and collect the flow-through. The fractions containing DiD labeled 
DNA LNCs were collected. After this purification step, the LNC concentration was 
low; a concentration step was therefore required.  
4. Add 12 ml maximum of collected fraction of DiD labeled DNA LNCs in a Amicon® 
Ultra-15 centrifugal filter devices. 
5. Centrifuge 30 min, 4000 rpm at room temperature. 
6. The thus concentrated DiD Labeled DNA LNCs are collected from the filter unit 
sample reservoir, while the ultrafiltrate is collected in the provided centrifuge tube. 
7. The DiD labeled DNA LNC concentration was fixed at 150 mg/ml. Place the DiD 
labeled DNA LNC suspension collected in the upper part to this reference 
concentration and to obtain a final NaCl concentration of 150 mM. 
8. Control the size, polydispersity and surface charge (zeta potential) of DiD labeled 
DNA LNCs thanks to dynamic light scattering (DLS, size) and electrophoretic 
mobility (zeta potential) (ex. Malvern Zetasizer®, Nano Series DTS 1060, Malvern 
Instruments S.A., Worcestershire, UK). 
9. Control the encapsulation properties of DiD labeled DNA LNCs thanks to 
electrophoresis migration of broken (Triton X100) or intact DNA LNCs in an agarose 
gel (1%) containing ethidium bromide (method developed in (5, 9)). 
e) Formulation of PEGylated DiD labeled DNA LNCs 
1. Weigh DSPE-mPEG2000 as a function of the wanted concentration in a vial. As an 
example, add 28.5 mg of DSPE-mPEG2000 for a final molar concentration of 10 mM.  
2. Add 1 ml of DiD labeled DNA LNCs in this vial. Mix by vortexing. 
3. Co-incubate polymers and purified DiD labeled DNA LNCs in a vial placed in a water 
bath, 4h at 30°C. 
4. After this co-incubation step, mix by vortexing and put the tube in an ice bath. 
 
3.1.2 Procedure for fluorescent labeling of cell penetrating peptides 
Cell-penetrating peptides (CPP) constitute promising tools for non-invasive cellular import of 
siRNA. CPP-based strategies have been successfully applied for ex vivo and in vivo delivery 
of therapeutic siRNA molecules. Recently, a new peptide-based system, CADY, has been 
described for efficient delivery of siRNA. CADY is a secondary amphiphatic peptide able to 
form stable non-covalent complexes with siRNA and to improve their cellular uptake. It is 
possible to modify this peptide for following CADY/siRNA complexes in vivo.  
The protocol described below outline (a) A general procedure suitable for conjugation of most 
thiol-reactive probes (iodoacetamides, maleimides) to peptides and (b) different procedures 
for peptide purifications.  
 
1. CADY (20-residues: Ac-GLWRALWRLLRSLWRLLWRA-cya; MW: 2653 Da) was 
synthesized by solid-phase peptide synthesis using AEDI-expensin resin with 
(fluorenylmethoxy)-carbonyl (Fmoc) continuous (Pionner, Applied Biosystems, 
Foster city, CA) as described previously (10). CADY was purified by semi-
preparative reverse-phase high performance liquid chromatography (RP-HPLC) and 
identified by electrospray mass spectrometry and amino acid analysis (10). The 
peptide is acetylated at its N-terminus and carried a cysteamide group at its C-
terminus.  
2. Take the vial containing the peptide powder out of the freezer and equilibrate for  
30 min at room temperature without opening the vial. Resuspend CADY at a final 
concentration of 2 mg/ml (774.5 µM) in ultra pure water RNAse, DNAse free and 2% 
DMSO. CADY powder should be first solubilized directly in DMSO, then add 
calculated volume of water to reach the 2 mg/ml final CADY concentration and 2% 
DMSO. 
3. Mix gently by tapping the tube and sonicate the CADY solution for 10 min in the 
water bath sonicator. Sonication is essential to prevent peptide aggregation and 
finalize solubilization. 
4. CADY (1 mM) was dissolved in Phosphate Buffer Saline (pH 7.5) at room 
temperature. At this pH, the C-terminal thiol group is nucleophilic and reacts 
exclusively with the fluorescent reagent. In contrast peptide amines are protonated 
and therefore not reactive. 
5. Prepare a 10 mM stock solution of the reactive dye (Maleimide-FITC or Maleimide-
Alexa from Molecular Probes. Inc., Invitrogen, Carlsbad, CA, USA) in DMSO and 
protect stock solutions from light by wrapping the tubes with an aluminum foil. 
Maleimide stock solutions can be stored at -20°C for a month.  
6. A step of reduction of disulfide bonds in the peptide can be added to the protocol 
using a 10-fold molar excess of TCEP reducing agent. For labeling with 
iodoacetamides or maleimides, TCEP can be kept in the solution during conjugation.  
7. Add 20 fold molar excess of the reactive dye drop wise to the peptide solution. 
8. Allow the reaction to proceed for 2 hours at room temperature or overnight at 4°C. 
For more detail see The Handbook: A Guide to Fluorescent Probes and Labeling 
Technologies (probes.invitrogen.com). 
9. Upon completion of the reaction with the protein, an excess of glutathione, and 2-ß-
mercaptoethanol, is present, ensuring that no reactive species are formed during the 
purification step. 
10. Fluorescently labeled peptide can be separate on a Sephadex G-25 columngel 
filtration column equilibrated in phosphate buffer saline (NAP-10 column). However, 
for in cellular or in vivo imaging, Fluorescently labeled peptides were further purified 
by RP-HPLC using a C18 reverse-phase HPLC column (Interchrom UP5 HDO/25M 
Modulo-cart Uptisphere, 250 mm x 10 mm) and identified by electrospray mass 
spectrometry.  
11. The degree of labeling can be calculated using the following formula: 
 
where Ax = the absorbance value of the dye at the absorption maximum wavelength. And e= 
molar extinction coefficient of the dye or reagent at the absorption maximum wavelength 
(according to The Handbook: A Guide to Fluorescent Probes and Labeling Technologies). 
The procedure for CADY-siRNA complex formation constitutes a major factor in the success 
and efficiency of CADY technology and should be followed carefully. It was well described 
previously in (11). 
 
3.1.3 Synthesis of PEI FluoR (Figure 1) 
A solution (1.5 mL) of borate buffer (0.2 M) was added into a vial containing 50 mg of PEI 
and the pH was adjusted to 8 by adding a solution of NaOH (10 M). 7.0 mg of 
tetramethylrhodamineisothiocyanate (RITC) was dissolved in 200 L of DMSO and the 
resulting solution was slowly added to the prior solution (under agitation). The reaction 
mixture was stirred overnight at room temperature with exclusion of light. TLC 
(CH2Cl2/MeOH; 80/20) of the reaction mixture was then carried to evaluate the presence of 
starting material RITC. If required, the product maybe purified by column chromatography 
(Sephadex G25 PD10) in water. 34 mg of PEI FluoR was isolated (75% yield) and was then 
dissolved in 1.8mL of water. The exact concentration of the PEI FluoR solution may be 
determined by proton NMR and colorimetric measurement at 493 nm (ca. 150 mM). 
 
The preparation of the PEI FluoR/nucleic acid complexes should be performed in a laminar 
flow hood using the sterile 10 % glucose solution.  
1. Dilute the nucleic acid (plasmid DNA or siRNA; Table 4) using the 10% glucose stock 
solution in ddH2O and sterile water to prepare a solution of ½ the injection volume of 
5 % glucose. Vortex gently or mix by pipetting up and down (Note 6). 
2. Dilute the PE-FluoR reagent using the 10% glucose stock solution and sterile water to 
prepare a solution of ½ the injection volume of 5% glucose. Vortex gently and spin 
down.   
3. Add the diluted PEI FluoR to the diluted nucleic acid all at once, vortex gently, spin 
down.  
4. Incubate for 15 min at room temperature. From this time point, the complexes are 
stable 2 h at room temperature and for 24 h if stored at 4ºC.  
5. Perform injections into animals using complexes equilibrated at room temperature 
(Table 4).  
6. The biodistribution of PEI-FluoR can be followed as early as 1 to 4 h following 
injection, using fluorescence of the whole animal or slices of fixed tissues depending 
on the target organ.   
7. Monitor gene expression as required at the appropriate time point (1–96 h after the last 
injection) depending on the mode of injection and the targeted organ.   
 
With the current formulation and delivery approaches employed today, silencing can be 
achieved in several tissues and cell types, most notably through direct delivery of siRNA to 
the back of the eye, to the central nervous system, and to lung epithelial cells, and through 
systemic delivery of siRNA to hepatocytes and tumor cells. 
 
3.2 Pharmacokinetic study by in vivo Fluorescence Reflectance imaging  
 
1. Mice are anesthetized (isoflurane/oxygen 3.5% for induction and 1.5% thereafter) and 
placed on a warm holder (37°C) for intravenous injection of the fluorescent mixture 
(100 to 200 µL) via the tail vein. 
2. Mice are immediately placed in dorsal position in the fluorescence imaging set up and 
a real time imaging sequence is acquired over 15 min. Afterwards anesthesia is 
suspended till the next imaging time point.   
3. One, 2, 3, 5 and 24 hours after injection fluorescence and bright field images are 
acquired in 4 mouse-body positions (ventral, dorsal and laterals). 
4. At 24 hours post injection mice are anesthetized and some blood is sampled by heart 
puncture. Mice are then sacrificed and the principal organs are removed (brain, heart, 
lungs, liver, spleen, pancreas, stomach, guts, kidneys, suprarenal glands, ovaries, 
uterus, muscle, fat, skin, lymph nodes). 
5. Blood is centrifuged (20 min, 2300 g, 4°C) and 200 µL of plasma are sampled for 
fluorescence imaging with the isolated organs. 
6. Each fluorescence image can be superimposed on the bright field image for better 
location of the fluorescent signal. Semi-quantitative data are obtained from the 
fluorescence images by drawing regions of interest (ROI) on the area to be quantified. 
The results are expressed as a number of Relative Light Units per pixel for a 100 ms 
exposure time (RLU/pix/100 ms). 
 
3.3 Luc gene transfer follow up by in vivo Bioluminescence imaging 
 
In vivo luciferase expression is monitored by bioluminescence 24 hours after luciferase gene 
transfer in vivo. 
1. The day of experimentation the solution is diluted to 10 mg/mL in DPBS without 
CaCl2 and MgCl2 and is kept sheltered from light. 
2. Vigil mice are injected intraperitonealy with D-Luciferin (150 mg/kg) just before 
anesthesia (isoflurane 4% for induction and 1.5% thereafter). 
3. Five minutes after Luciferin injection, bioluminescence images are acquired with the 
IVIS Kinetic (Caliper) (Figure 2). 
4. Semi-quantitative data are obtained from the bioluminescence images by using the 
Living image software (Caliper). Regions of interest (ROI) are drawn on the areas to 
be quantified. The results are expressed as a number of photons per pixel per second 
(ph/pix/s). 
5. After imaging, mice are sacrificed and the principal organs are removed for in vitro 
Luciferase activity measurement (brain, heart, lungs, liver, spleen, pancreas, stomach, 
guts, kidneys, suprarenal glands, ovaries, uterus, muscle, fat, skin, lymph nodes). 
 
3.4 LacZ gene transfer follow up by in vivo Fluorescence Reflectance 
imaging 
 
In vivo ß-Gal expression is monitored by NIR fluorescence 24 hours after LacZ gene transfer 
in vivo. 
1. Mice are anesthetized (isoflurane/oxygen 3.5% for induction and 1.5% thereafter) and 
placed on a warm mat (37°C) for intracardiac injection of DDAOG (100 µL). 
2. Twenty minutes after injection, fluorescence and bright field images are acquired for 4 
mouse-body positions (ventral, dorsal and laterals) (Figure 3). 
3. Just after imaging, mice are sacrificed and the principal organs are removed (brain, 
heart, lungs, liver, spleen, pancreas, stomach, guts, kidneys, suprarenal glands, 
ovaries, uterus, muscle, fat, skin, lymph nodes) for ex vivo fluorescence imaging. 
4. Each fluorescence image can be superimposed on the bright field image for better 
location of the fluorescent signal. Semi-quantitative data are obtained from the 
fluorescence images by drawing regions of interest (ROI) on the area to be quantified. 
The results are expressed as a number of Relative Light Units per pixel for a 100 ms 
exposure time (RLU/pix/100 ms). 
 
3.5 In vitro enzymatic assays on isolated organs 
 
Luciferase or ß-Gal activities are also assayed in vitro using the Luciferase Assay System or 
the ß-Gal Assay System (Promega) as recommended by the manufacturer. 
1. Tissues are extracted and cut into small pieces with a razor blade. Fragments are 
mixed thoroughly in 1 mL lysis buffer. 
2. After 15 minutes incubation, the samples are frozen at -20°C.  
3. The following day, the samples are thawed and brought to room temperature before 
centrifugation (2 min, 15 600 g). 
4. The supernatants are sampled for proteins content measurements using the DC-comp 
Bio-Rad assay (Bio-Rad, Marnes-la-Coquette, France) and luciferase or ß-Gal activity 
measurements. 
 
In vitro luciferase activity assay 
10 µL of the extract are mixed with 100 µL of luciferase assay substrate and the luciferase 
activity is measured for 10 s on a photoluminometer (Bethold, Thoiry, France). The luciferase 
activities are calculated as a number of Reference Light Unit per 10 s per mg of protein 
(RLU/10s/mg). As a reference, using purified firefly luciferase under the same experimental 
conditions, we determined that 2 ng of this enzyme produced 10
8
 RLU/10 s. 
 
In vitro ß-Gal activity assay 
50 µL of the extract are added to 50 µL of 2x Assay buffer and incubated 30 min at 37°C. The 
reaction is stopped by adding 150 µL of sodium carbonate 1 M and the absorbance is read at 
420 nm on a spectrophotometer (Bio-Rad, Marnes-la-Coquette, France). The ß-Gal activities 
are expressed as a number of milliUnits (mU) per mg of protein (One mU corresponding to 
the hydrolyze of 1 nmol of substrate per minute at pH 7.5 and 37°C). As a reference, using 
purified ß-Gal under the same experimental conditions, we determined that 2 ng of this 
enzyme produced 0.654 mU. 
 
 
 
  
4. Notes 
 
Note 1: Several sequence prediction websites exist for the determination of the sequence of a 
siRNA. They are often associated with companies that sell siRNA.  
• Whitehead siRNA Selection Web Server 
http://jura.wi.mit.edu/bioc/siRNAext – Developed and hosted by the Whitehead Institute, this 
website is somewhat more complex, giving a large number of possible duplexes along with 
their thermodynamic properties, etc. An off-target search can be done for each duplex, within 
the site but in a separate step. (siRNA Selection Server: an automated siRNA oligonucleotide 
prediction server Bingbing Yuan, Robert Latek, Markus Hossbach, Thomas Tuschl and Fran 
Lewitter). 
 Rosetta siRNA Design Algorithm 
Sigma-Aldrich has entered into an exclusive partnership with Rosetta Inpharmatics Sequence 
design : http://www.sigmaaldrich.com/life-science/your-favorite-gene-search.html. The 
Rosetta siRNA Design Algorithm utilizes Position-Specific Scoring Matrices (PSSM) and 
knowledge of the all-important siRNA seed region to predict the most effective and specific 
siRNA sequences for your target gene of interest. 
• BIOPREDsi algorithm 
Developed by the Novartis Institutes for BioMedical Research, this site features a very simple 
input and output, with only the essential information given (input is a gene Accession number 
or gene sequence, output is a user-defined number of optimized siRNA sequences: 
https://www.qiagen.com/geneglobe/default.aspx). 
siRNA targeting gene, and a derived siRNAharbouring two mismatches, must be used for 
each target gene as control. A BLAST search is carried out to ensure that the chosen 
sequence does not target unwanted genes.  
Fluorescent dyes are widely used to label at the 3' end or 5’ end of the sense strand siRNA for 
tracking of siRNA. Fluorescently labeled siRNA could be synthesized by different company 
according to the choosing sequences: Sigma (http://www.sigmaaldrich.com/life-science/) 
Dharmacon (www.dharmacon.com), Qiagen (https://www.qiagen.com), Ambion 
(http://www.invitrogen.com/site/us/en/home/brands/ambion.html), Eurogentec 
(https://secure.eurogentec.com). 
 
Note 2: Add a plastic paraffin film at the bottom of balloon, and gently shake avoiding the 
solvent to evaporate or to enter in contact with the plasti cparaffin film. 
Note 3: The stock solution of DiD in acetone (5mg/ml) can be stored at -20°C, in a well 
closed scintillation bottle. 
 
Note 4: As Solutol HS-15
® 
is viscous, this compound is weighted first, and could be added to 
the bottle with a syringe. 
 
Note 5: This protocol led to a final volume of 1.479 ml of DiD labeled DNA LNCs. When a 
higher volume is needed, the proportions of the different LNC compounds have to be 
multiplied. 
 
Note 6: the final concentration of nucleic acid is the injection volume should not exceed 0.5 
µg/µl 
  
Tables and figures : 
 
Target 
Fluorophore 
type 
Graftin
g group 
Reactive 
group 
pH range 
Examples 
Specific molecule Reactive 
Primary 
amine  
(-NH2) 
Isothicyanate ~ 9 FITC, RITC 
Succinimidyl 
ester 
~ 8 
Alexafluor®, 
Cydyes 
Thiol  
(-SH) 
Maleimide ~ 7 
Alexafluor®, 
Fluoprobes® 
Whole 
nanoparticle 
Hydrophobic 
None – non covalent 
interaction 
Any pH 
compatible 
with 
nanoparticle 
and 
fluorophore 
DiI, DiD 
 
Table 1. Selection criteria for the choice of a fluorescent probe. 
  
Maximum Absorption 
(Emisson) Wavelength in nm 
Fluorescent dye Dark dye 
633 (647) AF 633  
650 (670) AF 647, DiD, Cy5, IRdye 650  
660 (690) AF 660  QSY 21 
680 (700) AF 680, Cy5.5, IRdye 680 BHQ-3 
700 (720) AF 700, IRdye 700  
750 (775) AF750, DiR, Cy7, IRdye 750 IRdye QC-1 
Table 2: Fluorescent dyes grouped depending on their spectral properties and possible 
dark dye quenchers. 
 
  
  
Donor/acceptor 
pair 
Donor 
absorbance 
(nm) 
Donor 
emission 
(nm) 
Acceptor 
absorbance 
(nm)  
Acceptor 
emission 
(nm) 
QY 
L.mol
-1 
.cm
-1 
Förster 
Radius 
AF633/AF660 632 647 663 690 0.3 132000 6.5 
AF633/AF680 632 647 679 702 0.3 183000 7 
AF650/AF700 650 668 702 723 0.33 192000 7 
AF650/AF750 650 668 749 775 0.33 240000 6.5 
AF660/AF750 663 690 749 775 0.37 240000 7 
AF680/AF750 679 702 749 775 0.36 240000 7.5 
AF680/ 
IRdye800 
679 702 774 789 0.36 240000 7 
AF700/AF750 702 723 749 775 0.25 240000 7.5 
AR700/ 
IRdye800 
702 723 774 789 0.25 240000 7 
AF700/AF790 702 723 785 810 0.25 260000 7 
Table 3: Possible near infrared FRET pairs with absorptions and emissions maxima, 
donor fluorescence quantum yield, acceptor molar extinction coefficient (providers’ 
data) and estimated Förster radius (using providers’ data in water or PBS). 
  
Animal Site of injection Starting conditions 
Nucleic acid 
optimisation range 
Injection 
volume 
Optimisation 
range 
(5% glucose) 
Mouse 
IV Tail vein/ 
retro-orbital 
40 µg nucleic acid 
6.4 µl reagent 
200 µl of 5% glucose 
40 – 60 µg 
(1.6 - 2.4 mg/kg) 
200 - 400 µl 
Intraperitoneal 
IP 
100 µg nucleic acid 
16 µl reagent 
1 ml 5%glucose 
100 - 200 µg 
(4 - 8 mg/kg) 
1 ml 
Subcutaneous 
(s.c.) 
5 µg nucleic acid 
0.6 µl reagent 
10 µl of 5% glucose 
3 - 5 µg 5-15 µl 
 
Table 4: Recommended conditions for common administration routes in mice 
(http://www.polyplus-transfection.com/in-vivo-reagents-therapeutics/dna-sirna-delivery-in-
vivo-jetpei/) 
  
  
 
Figure 1: Schematic representation of the synthesis of PEI FluoR 
 
  
  
 
 
Figure 2: In vivolung bioluminescence imaging. Mice were injected intravenously with 50 
µg (200 µl) of luciferase plasmid DNA combined with “In vivo-PEI”. Whole_body 
Bioluminescence imaging was performed 24 h after DNA-PEI injection and 10 min after 
Luciferine ip injection. 
 
  
  
 
Figure 3: In vivo lung NIR fluorescence imaging. Mice were injected with 50 µg (200 µl) 
of ß-galactosidase plasmid DNA combined with “In vivo-PEI”. Whole-body fluorescence 
imaging was performed 24 h after complex DNA-PEI injection and after i.c. injection of 
DDAOG. 
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